What are the effects of Vorinostat?

Vorinostat (Vorinostat) is a histone deacetylase (HDAC) inhibitor that structurally belongs to the hydroxymate group. Other drugs in this group include Givinostat, Abexinostat, Panobinostat, Belinostat and Trichostatin A. These are emergency drugs with potential antitumor activity. These drugs were developed based on the recognition that in addition to genetic mutations, alterations in HDAC enzymes can affect the phenotypic and genotypic expression of cells, leading to dysregulation of homeostasis and tumor growth.

Vorinostat is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL). Vorinostat is a broad-spectrum inhibitor of HDAC activity and inhibits class I and class II HDAC enzymes, however vorinostat does not inhibit HDACs belonging to class III. HDAC inhibitors have multiple effects on cell types in vivo and in vitro, such as arresting growth, affecting cell differentiation and causing complete apoptosis of malignant cells. These drugs can be used either as monotherapy or in combination with other antineoplastic drugs. Although HDAC inhibitors have demonstrated anticancer effects, many aspects of their mechanisms remain incompletely understood.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.